Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for prevention and treatment of PTSD after emergency trauma surgery
ChiCTR2200056162Phase 4Recruiting
- Sponsor
- Xuzhou Central Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Xuzhou Central Hospital. Primary endpoints: PCL-5 scale score and Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Started Jan 2022; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on ChiCTR2200056162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056162.